查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010054

抗肥胖药物市场：依产品类型、剂型、给药途径及最终用户划分－2026-2032年全球市场预测

Anti-Obesity Drugs Market by Product Type, Dosage Form, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，抗肥胖药物市场价值将达到 43.8 亿美元，到 2026 年将成长到 46.7 亿美元，到 2032 年将达到 70.7 亿美元，复合年增长率为 7.07%。

主要市场统计数据
基准年 2025 43.8亿美元
预计年份：2026年 46.7亿美元
预测年份 2032 70.7亿美元
复合年增长率 (%) 7.07%

从策略角度审视现代抗肥胖治疗领域，重点关注临床进展、相关人员的期望以及专案可持续成功所面临的营运挑战。

抗肥胖药物的治疗格局已从小众临床争论发展成为生物製药公司、保险公司和医疗保健系统的主流策略重点。新型经营团队和联合治疗正在重新定义人们对持续减重和代谢改善的临床预期，重新激发了商业、临床和监管相关人员相关者的关注。这种转变要求在快速的治疗创新与长期安全性、用药依从性和成本效益等实际挑战之间取得平衡。

科学突破、不断发展的报销模式和新的给药方法如何重新定义肥胖治疗领域的竞争和护理路径。

抗肥胖药物市场正经历一场变革性的转变，其驱动力来自临床突破和保险公司的模式转移。肠促胰素生物学和双重促效剂平台的突破显着提高了药物疗效标准，改变了处方模式，并提高了人们对单纯减重之外的持续代谢获益的期望。这一科学动能正在引发一系列连锁反应，包括扩大适应症范围、考虑仿单标示外用药物以及加剧直接比较竞争，最终重塑药物生命週期规划和商业性上市策略。

分析 2025 年美国关税调整对整个减肥药生态系统的连锁反应，包括采购、製造重组、支付方保险覆盖范围和取得策略。

2025年美国关税调整对整个抗肥胖治疗价值链产生了连锁反应，加剧了依赖进口零件的脆弱性，并改变了成品的成本计算方式。生物製药和复杂小分子化合物的原料采购通常涉及多个国家的跨境运输。半成品关税的增加提高了接收成本，促使企业重新评估其供应商名单。为此，采购团队加快了供应商多元化进程，并探索远期合约以对冲投入品价格波动所带来的风险。

将产品模式、剂型、给药途径和最终用户环境与独特的临床和商业性机会联繫起来的详细細項分析。

基于细分市场的分析揭示了不同治疗领域、剂型、给药途径和终端用户的独特机会和限制因素，这些因素将影响产品组合和商业策略。从产品类型来看，GLP-1促效剂和双重促效剂因其高效性而备受临床医生青睐。同时，纳曲酮/安非他酮、奥利司他、芬特明/托吡酯和SGLT2抑制剂等成熟药物，在针对特定患者群体和合併症的处方中仍然发挥着至关重要的作用。由于作用机制和安全性特征的差异，治疗顺序、合併用药策略和禁忌症管理仍将是临床讯息的核心主题。

美洲、欧洲、中东和非洲以及亚太地区在临床应用率、支付方要求和监管复杂性方面的区域差异，正在推动各地采取不同的准入策略。

区域趋势在临床、监管和商业方面呈现出显着特征，因此需要製定本地化的市场进入和业务拓展策略。在美洲，强大的支付方影响力、大规模的临床试验部署以及患者对有效治疗方法的高需求，共同创造了一个竞争激烈的环境，长期治疗效果和成本效益证据至关重要。能够适应基于价值的合约和完善患者支援体系的製造商，将在专科诊所和广泛的门诊网路中都获得支援。

透过证据生成、供应弹性以及综合患者解决方案，制定竞争和企业策略，从而决定抗减肥药领域的长期领导地位。

抗减肥药市场的竞争格局由老牌製药公司和创新生物技术公司共同组成。市场领导正利用其深厚的临床开发能力拓展适应症并累积对比证据，而新参与企业则专注于差异化的作用机制、创新医疗设备或综合性的病患支援提案。随着各公司努力加速产品线成熟并扩大商业性影响力，策略联盟、共同开发契约和收购等手段正变得越来越普遍。

为製药公司和相关人员提供极具影响力和可操作性的建议，以确保药物可及性、加强价值链，并在临床实践中最大限度地发挥治疗价值。

行业领导者应优先考虑一系列切实可行的步骤，将临床潜力与可持续的商业性成果联繫起来。首先，投资于分阶段的证据生成计划，该计划将关键临床试验数据与旨在证明持续代谢效应和改善生活品质的可操作性真实世界研究相结合。儘早与保险公司和卫生技术评估机构合作，统一终点指标和证据包，将有助于减少后续准入的阻力。

一项严谨的多面向研究框架，结合了相关人员访谈、监管审查、临床证据整合和情境分析，得出了策略性结论。

本执行摘要的研究结合了多种方法，以确保提供平衡且切实可行的见解。研究人员对内分泌科和肥胖症科的临床医生、医院药剂师、支付方政策制定者以及供应链高管进行了初步的定性访谈，以识别短期运营风险和推动技术应用的因素。此外，研究人员还系统地审查了监管和临床指南文件以及公开的临床试验註册信息，以检验影响治疗定位、安全性信号和保险覆盖范围等讨论的关键终点指标。

结论强调，将临床创新转化为可持续的患者疗效需要证据协调、供应弹性以及在地化的准入策略。

现代抗肥胖药物领域呈现前所未有的治疗潜力，但同时也面临复杂的取得途径。科学创新提高了疗效标准，并改变了人们对慢性病管理的预期，但供应链和监管的复杂性，以及对药物可及性和可负担性的考量，都在减缓这些治疗方法转化为人群层面疗效的速度。因此，决策者必须整合临床、营运和商业性计划，才能实现长期价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：抗肥胖药物市场：依产品类型划分

  • GLP-1促效剂
  • 纳曲酮安非他酮
  • 奥利司他
  • 托吡拉芬特明
  • SGLT2抑制剂

第九章：以剂型分類的抗肥胖药物市场

  • 胶囊
  • 注射药物
    • 预填充笔
    • 管瓶
  • 药片

第十章：抗肥胖药物市场：依给药途径划分

  • 注射药物
    • 自动喷油器
    • 预填充笔
    • 管瓶
  • 鼻内
  • 口服

第十一章：抗肥胖药物市场：依最终用户划分

  • 诊所
  • 居家医疗
  • 医院

第十二章：抗肥胖药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：抗肥胖药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：抗肥胖药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国抗肥胖药物市场

第十六章：中国抗肥胖药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alvogen Iceland EHF
  • Amgen Inc
  • Arena Pharmaceuticals Inc
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • F Hoffmann La Roche Ltd
  • GlaxoSmithKline plc
  • Innovent Biologics Inc
  • LG Chem Ltd
  • Merck and Co Inc
  • Novo Nordisk AS
  • Pfizer Inc
  • Rhythm Pharmaceuticals Inc
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • VIVUS LLC
  • Zydus Lifesciences Ltd
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market was valued at USD 4.38 billion in 2025 and is projected to grow to USD 4.67 billion in 2026, with a CAGR of 7.07%, reaching USD 7.07 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.38 billion
Estimated Year [2026] USD 4.67 billion
Forecast Year [2032] USD 7.07 billion
CAGR (%) 7.07%

A strategic orientation to the modern anti-obesity therapy environment emphasizing clinical advances, stakeholder expectations, and operational imperatives for sustained program success

The therapeutic landscape for anti-obesity drugs has evolved from a niche clinical conversation into a mainstream strategic priority for biopharma, payers, and health systems. Novel incretin-based agents and combination therapies have reshaped clinical expectations for durable weight loss and metabolic benefit, prompting fresh interest across commercial, clinical, and regulatory stakeholders. This shift requires executives to reconcile rapid therapeutic innovation with real-world considerations such as long-term safety, adherence modalities, and cost-effectiveness.

Clinicians are increasingly viewing obesity as a chronic disease that demands sustained pharmacologic intervention alongside lifestyle modification. Payers are responding with conditional coverage frameworks that emphasize outcomes and value-based contracting. Simultaneously, manufacturing and distribution ecosystems are adapting to the unique requirements of injectable formulations and complex biologics. Taken together, these cross-cutting forces create both opportunity and complexity for organizations seeking to launch or scale anti-obesity therapeutics.

This introduction frames the rest of the executive summary by highlighting the intersection of innovation, access, and systems-level readiness. The following sections outline the transformative shifts in the therapeutic landscape, tariff-related supply chain implications, segmentation-driven commercial insights, regional dynamics, competitive positioning, actionable recommendations, methodological underpinnings, and concluding priorities for decision-makers. Each element is intended to inform strategic planning, identify operational risks, and prioritize high-impact interventions for near- and mid-term horizons.

How scientific breakthroughs, evolving reimbursement models, and new delivery modalities are jointly redefining competitive dynamics and care pathways in obesity therapeutics

The anti-obesity drug landscape is undergoing transformative shifts driven by simultaneous clinical breakthroughs and evolving payer paradigms. Breakthroughs in incretin biology and dual-agonist platforms have materially raised efficacy benchmarks, altering prescribing patterns and elevating expectations for sustained metabolic benefit beyond weight reduction alone. This scientific momentum has catalyzed a cascade of label expansions, off-label prescribing considerations, and intensified head-to-head competition, which in turn is reshaping life-cycle planning and commercial launch strategies.

Concurrently, reimbursement frameworks are adapting. Payer strategies now increasingly emphasize longitudinal outcomes, tiered access, and novel contracting models that tie reimbursement to performance metrics. Health systems are reorienting care pathways to integrate pharmacotherapy into multidisciplinary obesity management programs, which affects utilization patterns across ambulatory clinics, hospitals, and homecare settings. Additionally, the proliferation of injectable delivery formats has introduced new logistics and patient education imperatives that manufacturers must address to ensure adherence and real-world effectiveness.

Together, these shifts require companies to pivot from product-centric launches toward integrated ecosystem plays that align clinical evidence generation, patient support services, and dynamic pricing approaches. Strategic differentiation will be achieved by those who can demonstrate durable outcomes, operationalize scalable distribution models, and collaborate effectively with payers and providers to lower barriers to long-term access.

An analysis of how the 2025 U.S. tariff adjustments reverberated through procurement, manufacturing realignment, payer coverage, and access strategies across the obesity drug ecosystem

U.S. tariff adjustments in 2025 created a ripple effect across the anti-obesity therapeutic value chain, amplifying vulnerabilities in import-dependent components and altering cost calculus for finished products. Raw material sourcing for biologics and complex small molecules often crosses multiple borders; tariffs on intermediate goods increased landed costs and incentivized firms to reevaluate supplier footprints. In response, procurement teams accelerated supplier diversification and explored forward contracts to hedge input-price volatility.

Manufacturers also reassessed global manufacturing footprints and considered nearshoring options to reduce exposure to tariff-induced price swings. This strategic realignment carries nontrivial implications for capacity planning, technology transfer timelines, and regulatory submissions, since moving production or altering supplier lists requires time-consuming validation and potential inspections by health authorities. Those delays can defer launches and complicate inventory planning for high-demand injectables, which are sensitive to cold-chain integrity and lead times.

Payers and providers reacted to increased product costs by tightening formulary placement and intensifying utilization management. Coverage policies leaned more heavily on prior authorization criteria tied to comorbidity profiles and demonstrated response, while some health systems increased their emphasis on cost-mitigating alternatives such as nonpharmacologic interventions or legacy oral agents. At the same time, manufacturers with vertically integrated supply chains or domestic production capability enjoyed a relative advantage, securing continuity of supply and greater pricing flexibility. In sum, tariff-driven pressures reinforced the strategic value of supply chain resilience, regulatory agility, and proactive stakeholder engagement to preserve patient access and commercial momentum.

Detailed segmentation insights linking product modality, dosage form, administration route, and end-user settings to distinct clinical and commercial opportunities

Segmentation-based analysis reveals differentiated opportunities and constraints across therapeutic, dosage, administration, and end-user vectors that should shape portfolio and commercial strategies. Based on product type, GLP-1 agonists and dual-agonist modalities are driving clinician demand through high-efficacy outcomes, while established agents such as naltrexone-bupropion, orlistat, phentermine-topiramate, and SGLT2 inhibitors retain relevance for specific patient cohorts and comorbidity-driven prescribing. Differing mechanisms of action and safety profiles mean that treatment sequencing, combination strategies, and contraindication management will remain central to clinical messaging.

Dosage form considerations materially influence patient adoption and supply chain design. The market's injectable formats, which include prefilled pens and vials, demand robust cold-chain logistics and comprehensive patient education programs to optimize adherence. Capsules and tablets retain advantages in convenience and prescribing simplicity, which can be critical where cost or patient preference limits injectable uptake. Consequently, lifecycle management must account for both clinical differentiation and practical delivery constraints to maximize uptake across diverse settings.

Route of administration further stratifies commercial and clinical strategies. Injectable pathways, including autoinjectors, prefilled pens, and vials, require investment in nurse and pharmacist training, remote monitoring support, and device ergonomics to reduce administration barriers. Nasal and oral routes offer differentiated value propositions for rapid onset or convenience, which can expand reach among patients with injection hesitancy. Finally, end-user segmentation into clinics, homecare settings, and hospitals influences distribution choices, channel economics, and the design of patient support services. Clinics and hospital outpatient programs often serve as early adopters for higher-acuity cases, while homecare services are increasingly central to chronic therapy adherence and long-term retention.

Regional variations in clinical adoption, payer requirements, and regulatory complexity driving differentiated access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exhibit distinct clinical, regulatory, and commercial contours that require tailored strategies for market entry and scale-up. In the Americas, strong payer influence, large-scale clinical adoption, and high patient demand for efficacious therapies create a competitive environment where evidence of long-term outcomes and cost-effectiveness is paramount. Manufacturers that can align with value-based contracting and patient-support infrastructure will find traction in both specialty clinics and broader ambulatory networks.

Europe, Middle East & Africa presents a heterogeneous landscape characterized by variable regulatory pathways, divergent reimbursement philosophies, and differing levels of clinical infrastructure. National health systems and regional payers often require more rigorous health technology assessments and comparative-effectiveness data, which increases the importance of region-specific evidence generation and early HTA engagement. In markets where public coverage is constrained, private pay and clinic-based models may drive initial uptake, and partnerships with regional distributors can optimize access.

Asia-Pacific is defined by rapid adoption in urban centers, diverse regulatory timelines, and a mix of public and private payer structures. High population density and increasing prevalence of cardiometabolic comorbidities make the region strategically critical, but manufacturers must navigate price sensitivity, differential prescribing practices, and growing local competition. Across all regions, a coherent approach to regulatory harmonization, local clinical data generation, and tailored patient-support ecosystems will be necessary to translate clinical promise into sustainable access and outcomes.

Competitive dynamics and corporate strategies that determine long-term leadership in anti-obesity therapeutics through evidence generation, supply resilience, and integrated patient solutions

Competitive positioning in the anti-obesity therapeutics arena is being shaped by a mix of established pharmaceutical companies and innovative biotechnology entrants. Market leaders are leveraging deep clinical development capabilities to expand indications and generate head-to-head evidence, while newer entrants are focusing on differentiated mechanisms, device innovation, or integrated patient-support propositions. Strategic partnerships, co-development agreements, and acquisitions are common as firms seek to accelerate pipeline maturation and extend commercial reach.

Companies that integrate robust outcomes data with scalable patient services will gain a competitive edge in payer negotiations and provider adoption. Those with strong manufacturing footprints and supply chain redundancy demonstrate advantage in maintaining continuity of supply during demand fluctuations. In parallel, firms investing in device ergonomics, digital adherence tools, and multidisciplinary care models are better positioned to address real-world effectiveness and retention challenges.

Intellectual property strategies and lifecycle management plans will also determine long-term positioning, particularly as biosimilar and small-molecule competitors enter the mix. Proactive management of regulatory exclusivities, device patents, and formulation improvements can extend commercial viability. Ultimately, companies that align clinical differentiation with operational excellence and payer-centric evidence will lead in converting scientific promise into sustained patient access.

High-impact, implementable recommendations for manufacturers and stakeholders to secure access, strengthen supply chains, and maximize real-world therapeutic value

Industry leaders should prioritize a set of actionable interventions that connect clinical promise to durable commercial outcomes. First, invest in a phased evidence generation plan that pairs pivotal trial data with pragmatic real-world studies designed to demonstrate sustained metabolic and quality-of-life benefits. Early engagement with payers and HTA bodies to align endpoints and evidence packages can reduce downstream access friction.

Second, strengthen supply chain resilience by diversifying suppliers, accelerating qualification of alternate sites, and exploring nearshoring where appropriate to mitigate tariff and logistical risk. Parallel investments in cold-chain capacity and inventory management systems will be crucial for high-demand injectables. Third, design patient support models that address initiation and long-term adherence: build multichannel education for injection technique, leverage digital adherence tools, and coordinate with clinics and homecare providers to create continuity of care.

Fourth, adopt flexible commercial models that include outcomes-based contracting, tiered pricing, and indication-specific formulary strategies. Tailor messaging and patient journeys to administration route and dosage form preferences, and optimize device design to reduce friction. Finally, pursue strategic collaborations for distribution, telehealth integration, and local evidence generation to accelerate access across heterogeneous regional markets. Executing these actions in parallel will materially enhance the probability of sustained uptake and payer alignment.

A rigorous multi-method research framework combining stakeholder interviews, regulatory review, clinical evidence synthesis, and scenario analysis to drive strategic conclusions

The research underpinning this executive summary combined a multi-method approach to ensure balanced, actionable insights. Primary qualitative interviews were conducted with clinicians across endocrinology and bariatric medicine, hospital pharmacy directors, payer policy leads, and supply chain executives to surface near-term operational risks and adoption drivers. Regulatory and clinical guidance documents were systematically reviewed alongside public trial registries to validate therapeutic positioning, safety signals, and endpoints shaping coverage discussions.

Quantitative synthesis drew on prescription trends from public health data, clinical trial outcome reporting, and product approvals to map adoption trajectories and identify channel-centric demand signals. Scenario planning techniques were applied to evaluate tariff impacts, manufacturing reallocation timelines, and potential payer responses under varying cost and supply conditions. Finally, cross-functional workshops with commercial, medical affairs, and regulatory experts informed the development of pragmatic recommendations that balance clinical rigor with commercial reality.

Quality assurance measures included triangulation across multiple data sources, validation of key findings with subject-matter experts, and sensitivity analysis around supply chain assumptions. The resulting methodology prioritizes transparency, replicability, and strategic relevance to support executive decision-making.

Concluding synthesis underscoring the necessity of coordinated evidence, supply resilience, and localized access strategies to convert clinical innovation into sustained patient outcomes

The contemporary anti-obesity drug environment is defined by unprecedented therapeutic potential and complex access dynamics. Scientific innovation has raised the bar for efficacy and shifted expectations around chronic disease management, yet access and affordability considerations, coupled with supply chain and regulatory complexity, temper the pace at which those therapies translate to population-level impact. Decision-makers must therefore integrate clinical, operational, and commercial planning to realize long-term value.

Sustainable success will favor organizations that proactively align evidence generation with payer expectations, build resilient and flexible supply chains, and design patient-centric delivery models that reduce adherence barriers. Regional heterogeneity demands localized strategies that respect regulatory norms and payer decision-making frameworks while leveraging global evidence. Taken together, the path forward requires coordinated action across functions and stakeholders to convert clinical advances into meaningful, equitable patient outcomes.

This conclusion underscores the imperative for timely, evidence-informed strategy execution: firms that move decisively to reconcile clinical innovation with pragmatic access solutions will capture the first-mover advantages in a rapidly evolving therapeutic category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Drugs Market, by Product Type

  • 8.1. Glp-1 Agonists
  • 8.2. Naltrexone Bupropion
  • 8.3. Orlistat
  • 8.4. Phentermine Topiramate
  • 8.5. Sglt2 Inhibitors

9. Anti-Obesity Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Injectables
    • 9.2.1. Prefilled Pens
    • 9.2.2. Vials
  • 9.3. Tablets

10. Anti-Obesity Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Autoinjector
    • 10.1.2. Prefilled Pen
    • 10.1.3. Vial
  • 10.2. Nasal
  • 10.3. Oral

11. Anti-Obesity Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Anti-Obesity Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Obesity Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Obesity Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Anti-Obesity Drugs Market

16. China Anti-Obesity Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alvogen Iceland EHF
  • 17.6. Amgen Inc
  • 17.7. Arena Pharmaceuticals Inc
  • 17.8. AstraZeneca plc
  • 17.9. Bayer AG
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. Currax Pharmaceuticals LLC
  • 17.12. Eli Lilly and Company
  • 17.13. F Hoffmann La Roche Ltd
  • 17.14. GlaxoSmithKline plc
  • 17.15. Innovent Biologics Inc
  • 17.16. LG Chem Ltd
  • 17.17. Merck and Co Inc
  • 17.18. Novo Nordisk A S
  • 17.19. Pfizer Inc
  • 17.20. Rhythm Pharmaceuticals Inc
  • 17.21. Takeda Pharmaceutical Company Limited
  • 17.22. Teva Pharmaceutical Industries Ltd
  • 17.23. VIVUS LLC
  • 17.24. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 133. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 162. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)